



## Media Release

### Medacta publishes 2024 Annual General Meeting invitation

CASTEL SAN PIETRO, 9 April 2024 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Tuesday, 7 May 2024 at 11.00 am at the Group premises in Via alla Rossa 6, Rancate, Switzerland.

Shareholders can register to attend the Annual General Meeting in person but will also be able to vote their shares by giving a power of attorney and related voting instructions to the independent proxy or to a third-party proxy (who needs not be a shareholder).

Shareholders will be given the opportunity to submit questions to the Board of Directors ahead of the Annual General Meeting on Agenda Items via email to [investor.relations@medacta.ch](mailto:investor.relations@medacta.ch).

The Board of Directors is proposing to the AGM the distribution of CHF 11.0 million or CHF 0.55 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.

The Board is proposing the re-election of Dr. Alberto Siccardi as Chairman of the Board of Directors as well as of the other current board members, all of whom stand for re-election. The Board is also proposing the re-election of the members of the Remuneration Committee and the approval of the maximum amount of compensations for the members of the Board of Directors and the Group Executive Management. Further motions include the re-election of the Independent Proxy Holder and Auditors for the financial year 2023.

All details on the motions can be found in the invitation to the 2024 AGM at <https://www.medacta.com/EN/agm>.

#### Contact

Medacta International SA  
Giorgio Botta, Head of Investor Relations  
Phone: +41 91 696 14 95  
[investor.relations@medacta.ch](mailto:investor.relations@medacta.ch)

#### About Medacta

*Medacta is an international company specializing in the design, production, and distribution of innovative orthopedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 55 countries.*